Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Swollen lymph nodes serve as a crucial early warning system when the body fights HIV. These changes often appear subtle at first but persist beyond the duration of typical viral infections.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research published in The Lancet medical journal. The drug lenacapavir passed a critical ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

Incidence assays for differentiating early from established HIV infection To understand the epidemiology of HIV, the incidence of infection must be estimated. Immunoassays for assessing prevalence ...